For instance, studies using the IL-6 receptor blocker tocilizumab (TCZ) in mouse models have demonstrated its ability to ameliorate the pathological changes associated with DKD (13), further supporting the feasibility of targeting IL-6. The gene discussed is IL6; the disease is diabetic kidney disease.